Phathom Pharmaceuticals 提前完成 Voquezna®（Vonoprazan）治疗嗜酸性粒细胞性食管炎（EoE）的二期研究患者招募

美股速递06-23 20:00

Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎（EoE）的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®（Vonoprazan）的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1131031397?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-23 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131031397","market":"us","top_or_hot":-1,"title":"Phathom Pharmaceuticals 提前完成 Voquezna®（Vonoprazan）治疗嗜酸性粒细胞性食管炎（EoE）的二期研究患者招募","media":"美股速递","content":"<p>Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎（EoE）的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®（Vonoprazan）的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phathom Pharmaceuticals 提前完成 Voquezna®（Vonoprazan）治疗嗜酸性粒细胞性食管炎（EoE）的二期研究患者招募</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhathom Pharmaceuticals 提前完成 Voquezna®（Vonoprazan）治疗嗜酸性粒细胞性食管炎（EoE）的二期研究患者招募\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-23 20:00 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎（EoE）的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®（Vonoprazan）的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"","article_id":"1131031397","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131031397","pubTimestamp":1782216015,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎（EoE）的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®（Vonoprazan）的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PHAT":"Phathom Pharmaceuticals","BK4007":"制药"},"translate_title":"Phathom Pharmaceuticals completes Voquezna ahead of schedule ® (Vonoprazan) in the treatment of eosinophilic esophagitis (EoE)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Phathom Pharmaceuticals 已提前完成其针对嗜酸性粒细胞性食管炎（EoE）的二期临床试验 Phalcon-Eoe-201 的患者招募工作。该试验旨在评估其药物 Voquezna®（Vonoprazan）的疗效与安全性。这一进展标志着公司在推进该创新疗法的临床开发道路上迈出了关键一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131031397","isCrawlerRequest":true}